Advertisement

Topics

Tocagen Adopts “Seamless Pivotal Trial” for Brain Cancer Therapy

11:23 EDT 27 Oct 2017 | Xconomy

Three-year survival rates are rarely reported for a deadly form of brain cancer known as recurrent, high-grade glioma (HGG). Under the current standard of care, the median survival rate is seven to nine months. Yet San Diego-based Tocagen (NASDAQ: TOCA) says five patients in a high-dose cohort of its gene therapy treatment Toca 511 and […]

Related Biotechnology, Pharmaceutical and Healthcare News

Original Article: Tocagen Adopts “Seamless Pivotal Trial” for Brain Cancer Therapy

NEXT ARTICLE

More From BioPortfolio on "Tocagen Adopts “Seamless Pivotal Trial” for Brain Cancer Therapy"

Quick Links
Advanced Search | Login | Subscribe | RSS

Quick Search
Advertisement
 

Relevant Topics

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...

Biological Therapy
Biological therapy involves the use of living organisms, substances derived from living organisms, or laboratory-produced versions of such substances to treat disease. Some biological therapies for cancer use vaccines or bacteria to stimulate the body&rs...


News Quicklinks

Search Biotech, Medical and Healthcare News

Popular Biotech, Medical and Healthcare News

Biotech News by Article Type

BioPortfolio Bloggers

Publishing Your News on BioPortfolio

Recent Visitor News Searches


BioPortfolio Limited Social Media
Publish Content Agreements
Tools Help

HON Code certificate This site complies with the HONcode standard for trustworthy health information:
Verify here.

The information provided by BioPortfolio.com is not a substitute for professional medical advice, diagnosis or treatment. The BioPortfolio site is sponsored BioPortfolio Limited with offices at Stafford House, 10 Prince of Wales Road, Dorchester, DT1 1PW, England. If you are a legal copyright holder or a designated agent for such and you believe a post on this website falls outside the boundaries of “Fair Use” and legitimately infringes on your or your client's copyright we may be contacted concerning copyright matters at: priority@bioportfolio.com.
All rights reserved. All other trademarks recognized. Copyright © 1997-2017 BioPortfolio Limited. Site developed by Alacrify Ltd.